ID 109496
Author
Yamaguchi, Kunihisa Department of Urology, Institute of Health Biosciences, the University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Izaki, Hirofumi Department of Urology, Institute of Health Biosciences, the University of Tokushima Graduate School KAKEN Search Researchers
Takahashi, Masayuki Department of Urology, Institute of Health Biosciences, the University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Fukumori, Tomoharu Department of Urology, Institute of Health Biosciences, the University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Nishitani, Masaaki Kawashima Hospital
Sutou, Yasushi Tsurugi Municipality Handa Hospital
Uema, Kenzou Tokushima Red Cross Hospital
Kawano, Akira Sanuki Municipal Hospital
Hamao, Takumi Kamei Hospital
Kanayama, Hiro-omi Department of Urology, Institute of Health Biosciences, the University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Keywords
hormone therapy
discontinuation
PSA value
testosterone level
PSA relapse
Content Type
Journal Article
Description
Introduction : We evaluated changes in levels of prostate-specific antigen (PSA) and testosterone following discontinuation of long-term hormone therapy for non-metastatic prostate cancer. Patients and Methods : Treatment was discontinued in 31 patients
with non-metastatic prostate cancer (clinical stage B-C) after≧5 years of hormone therapy, during which time PSA level had been maintained less than 0.5 ng/ml. PSA and testosterone levels were measured after discontinuation of therapy. PSA>4.0 ng/ml was defined as PSA relapse in this study. Results : Mean age at discontinuation of hormone therapy was 78.7 years (range, 66-90). Mean duration of follow-up after discontinuation of therapy was 25.5 months. PSA non-relapse rate was quite high (87.1%). 4 of the 31 patients showed PSA relapse, after 12-24 months. Testosterone level exceeded castration level (<1.0 ng/ml) in 3 patients, each of whom developed PSA relapse. Conclusions : During follow-up, the PSA relapse rate was relatively low. These results suggest that treatment may be safely discontinued in many prostate cancer patients. In addition, rate of testosterone recovery after treatment discontinuation may be associated with PSA relapse. When considered the adaptation of discontinued, or intermittent hormone therapy for aged people, these findings may be useful.
Journal Title
The journal of medical investigation : JMI
ISSN
13431420
NCID
AA11166929
Volume
61
Issue
1-2
Start Page
35
End Page
40
Sort Key
35
Published Date
2014-02
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences
University Hospital